Was Eli Lilly Stock’s 45% Run Visible Early?
For questions about this article or underlying research, email help@trefis.com.
Eli Lilly (LLY) stock returned 45.3% in the six months from May 18 to November 16, 2026. The company’s sales kept rising over that stretch, led by its incretin drugs for diabetes and obesity, Mounjaro and Zepbound. Management also raised its full-year financial guidance in October. How early could an investor have seen that demand coming?

Lilly Showed Rising Supply And Sales From Early 2025
The first sign came on February 6, 2025, on Lilly’s call for the quarter ended December 2024. Management said the company had strengthened its supply and met its production target for salable doses. For an investor, that was an early hint that Lilly would have far more of its drugs to sell.
The call on August 7, 2025 added more. Lilly had increased production of salable incretin doses, management said, and had gained market share in that drug class for a fourth quarter. On the October 30, 2025 call, management said Mounjaro’s performance had accelerated on strong uptake around the world.
The filed quarters told the same story. Revenue in the quarter ended March 2025 was $12.7 billion, up 45.2% from a year earlier. It rose in every quarter after that, reaching $19.8 billion in the quarter ended March 2026, up 55.5%. That report was filed on April 30, 2026, and the shares jumped 9.8% that day. Even so, they finished May 18 down 3.0% from November 17, 2025, in the six months just before the window began. The first of these signs was public for more than a year before the six months measured here.
Lilly Outran Its Peers While Two Drugs Led Sales
Over the same six months, the S&P 500 returned 0.7%. Other drugmakers rose too, with Johnson & Johnson, Merck and Pfizer returning between 17.6% and 30.0%, but none matched Lilly.
Revenue grew by nearly $7 billion from a year earlier in the quarter ended September 2026, management said on the October 29, 2026 call. Mounjaro and Zepbound supplied $6 billion of that growth. Together the two drugs brought in more than $16 billion, against the $24.4 billion of revenue Lilly reported for that quarter. That is about two-thirds of the company’s sales coming from two medicines.
Is The Demand Behind Lilly Still Building?
Use of Lilly’s incretin drugs is still rising, but Lilly’s revenue growth has slowed. Growth from a year earlier eased in each quarter of 2026, from 55.5% in the quarter ended March to 38.6% in the quarter ended September. Management also said that about $900 million of September quarter revenue came from one-time items, including milestone payments.
On the other side, US use of incretin drugs for obesity grew 82% in the September quarter, management said. Since the Medicare GLP-1 bridge program began on July 1, more than half a million people had filled a prescription for a Lilly medicine through it. Management gave that figure on its October 29, 2026 call.
The combined revenue of Mounjaro and Zepbound is the figure to watch when Lilly next reports, expected in February 2027.
Lilly’s earliest evidence was public long before the six months measured here, and no one could have said when the market would act on it. Owning a group of strong companies, rather than one, means you do not have to guess.
Why Own One Leader When You Can Own 30?
If you like finding quality companies like Eli Lilly, the Trefis High Quality (HQ) Portfolio holds 30 of them in equal weight, and has returned more than 105% since its September 2020 launch. You’re welcome to look inside.
Spot an error or want more like this? Tell us in 10 seconds.